Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Entinostat + Exemestane + Goserelin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Entinostat||HDAC inhibitor SNDX-275|MS 275||HDAC Inhibitor 38||Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217, PMID: 32503469).|
|Exemestane||Aromasin||Aromatase Inhibitor 3||Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary).|
|Goserelin||Zoladex||Goserelin acetate||Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females, and is FDA approved for use in prostate carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02115282||Phase III||Exemestane + Goserelin Entinostat + Exemestane + Goserelin||Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic||Active, not recruiting|